no official package insert Clinical trial status / No completed Phase III trials in humans for TB-500 specifically Bulk drug substance status / Subject to ongoing FDA review for compounding eligibility DEA scheduling / TB-500 is not a controlled substance Key safety concern / No large-scale human safety data from randomized controlled trials Regulatory trend / FDA has increased scrutiny of peptide compounding since 2023 Parent molecule research / Thymosin beta-4 studied in wound healing and cardiac repair preclinical models TB-500 Has No FDA Approval TB-500 has never been submitted to or approved by the FDA through a New Drug Application (NDA) or Biologics License Application (BLA)
What this GHK-Cu dosage calculator does A ghk cu calculator like this is designed for one job: turn whats in the vial and how much liquid you added into a concentration, then convert your target amount into a volume you can measure
PubMed, Youssefi, Masoud, et al
Zhou R, Wang H, Yang Y, Zhang C, Dong X, Du J, et al
Headaches are an uncommon but reported mild side effect in a small subset of users, particularly when starting supplementation or at higher doses
Among these, 1 in 4 will likely have a repeated infection